// App-Quantinova.ai

2793 : Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Researchers

Presenter

  • H. Jean Khoury

Principal Investigators

  • Jeff H Lipton

  • Carlo Gambacorti-Passerini

  • Tim H Brummendorf

  • Dong-Wook Kim

  • Eric Leip

  • Virginia Kelly

  • Nadine Besson

  • Kathleen Turnbull

  • Hagop M. Kantarjian

Medical Centers

  • Yeouido St. Mary Hospital, Seoul, Korea

  • Universitatsklinikum Aachen, RWTH Aachen, Germany

  • University of Milano-Bicocca, Monza, Italy

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

  • Germany

  • Republic of South Korea

  • Italy

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Interferon

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved